pennystockhaven
  • Facebook
  • Google
  • Pinterest
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Commentary » Keryx Biopharmaceuticals (Nasdaq:KERX): Bounce Candidate

Keryx Biopharmaceuticals (Nasdaq:KERX): Bounce Candidate

Posted on April 2, 2012 by PennyStockHaven in Commentary, Stock Market News - No Comments

Shares of Keryx Biopharmaceuticals (Nasdaq:KERX) got slammed today after the company announced that their cancer drug trial, KRX-0401 (in-licensed by Keryx from AeternaZentaris Inc. (AEZS) in the United States, Canada and Mexico), failed.

Ron Bentsur, Chief Executive Officer of Keryx, stated:

We are all extremely disappointed with the results of the study. We thank the investigators who participated in what we believe was a well-run study, despite the outcome. We will evaluate whether our Phase 3 study of Perifosine in relapsed/refractory multiple myeloma will continue as planned. With approximately $31 million in cash as of March 31, 2012, and a well-controlled burn rate, we plan to focus our resources on the pending completion of the Zerenex (ferric citrate) long-term Phase 3 study for end stage renal disease (ESRD) patients with hyperphosphatemia, expected in the fourth quarter of 2012, and the New Drug Application (NDA) filing for Zerenex which will hopefully follow shortly thereafter.

Take a note on the Mr.Bentsur statement about Zerenex (above). This should be a “life-saver” for the company:

Zerenex (ferric citrate) is an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S. Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and the Phase 3 clinical program of Zerenex is ongoing under an SPA agreement with the FDA. Zerenex is also in Phase 3 development in Japan by our Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

Zerenex short-term Phase 3 efficacy study was initiated in May 2010, and was completed in November 2010. Zerenex met the primary and key secondary endpoints in the study.

Zerenex long-term Phase 3 safety and efficacy study was initiated in September 2010 and is ongoing.

In addition, Zerenex is in Phase 3 development in Japan by our Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

KERX stock traded almost 10X of its 10day average volume as of 11 a.m. EST


penny stock KERX

Keryx Biopharmaceuticals, Inc.
750 Lexington Ave. – 20th Floor
New York, NY 10022
Phone: 1-212-531-5965
Fax: 1-212-531-5961
http://www.keryx.com/

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.

AeternaZentaris, AEZS, KERX, Keryx Biopharmaceuticals, Nasdaq penny stock

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • ReWalk Robotics (RWLK): Yesterday, Today and Tomorrow

    June 8, 2019
  • Amyris, Inc. (AMRS): How to Mislead Investors

    April 21, 2019
  • ADMA Biologics, Inc. (ADMA): Offering is Imminent

    April 11, 2019
  • Proteostasis Therapeutics (PTI): Market Overreaction

    March 26, 2019
  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018
  • Light Engine Design Corp (TLED): 50% gain into your pocket

    November 7, 2017
  • This Oil Company Is Poised For A Huge Run

    October 24, 2017
  • Curis, Inc. (CRIS) – Alert is still in Effect

    October 11, 2017
  • Curis, Inc. (CRIS) – Volume Alert (Technical Play)

    October 4, 2017
    Micro & Small Cap Stocks

    * required

    *



    *



     
    Remember, if you’re not fully satisfied with our service, you can always opt-out of receiving our newsletter. We don’t spam and we’ll never sell your email to anyone else. We respect our subscribers’ privacy.

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Stocks

    • Financial Network
    • Free Investment Newsletter
    • Penny Stocks
    • Public Relations and Subscription Services
    eBay sniper

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2018 PennyStockHaven.com. All Rights Reserved